Targeting the sarcomere in inherited cardiomyopathies
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Variants in >12 genes encoding sarcomeric proteins can cause various cardiomyopathies. The two most common are hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Current therapeutics do not target the root causes of these diseases, but attempt to prevent disease progression and/or to manage symptoms. Accordingly, novel approaches are being developed to treat the cardiac muscle dysfunction directly. Challenges to developing therapeutics for these diseases include the diverse mechanisms of pathogenesis, some of which are still being debated and defined. Four small molecules that modulate the myosin motor protein in the cardiac sarcomere have shown great promise in the settings of HCM and DCM, regardless of the underlying genetic pathogenesis, and similar approaches are being developed to target other components of the sarcomere. In the setting of HCM, mavacamten and aficamten bind to the myosin motor and decrease the ATPase activity of myosin. In the setting of DCM, omecamtiv mecarbil and danicamtiv increase myosin activity in cardiac muscle (but omecamtiv mecarbil decreases myosin activity in vitro). In this Review, we discuss the therapeutic strategies to alter sarcomere contractile activity and summarize the data indicating that targeting one protein in the sarcomere can be effective in treating patients with genetic variants in other sarcomeric proteins, as well as in patients with non-sarcomere-based disease. Variants in genes encoding sarcomeric proteins can cause hypertrophic or dilated cardiomyopathy. In this Review, the authors discuss therapeutic strategies to target the cardiac sarcomere, focusing on four small molecules that have been developed that inhibit or activate the myosin motor protein to decrease or increase contractile force, respectively. Variants in genes encoding sarcomeric proteins are a leading cause of cardiomyopathies that are characterized by protein-specific molecular mechanisms of disease. Sarcomeric proteins can be targeted by small molecules to directly modulate contractile function in cardiac muscle. Small molecules that are targeted to the myosin heavy chain modulate enzymatic activity and/or availability of the myosin motor, leading to an increase or decrease in force production. Small molecules that target the myosin heavy chain, such as mavacamten and aficamten, can act via distinct molecular mechanisms that lead to altered myosin function. Sarcomere pharmacology suggests that small molecules targeting a specific sarcomeric protein will be effective even in patients with a causal variant in a gene encoding another sarcomeric protein. Variants in genes encoding sarcomeric proteins are a leading cause of cardiomyopathies that are characterized by protein-specific molecular mechanisms of disease. Sarcomeric proteins can be targeted by small molecules to directly modulate contractile function in cardiac muscle. Small molecules that are targeted to the myosin heavy chain modulate enzymatic activity and/or availability of the myosin motor, leading to an increase or decrease in force production. Small molecules that target the myosin heavy chain, such as mavacamten and aficamten, can act via distinct molecular mechanisms that lead to altered myosin function. Sarcomere pharmacology suggests that small molecules targeting a specific sarcomeric protein will be effective even in patients with a causal variant in a gene encoding another sarcomeric protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Truncations of titin causing dilated cardiomyopathy
Herman, D. S., Lam, L., Taylor, M. R. G., Wang, L., Teekakirikul, P., Christodoulou, D., Conner, L., DePalma, S. R., McDonough, B., Sparks, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110186 · Cited by 1,485
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Marian, A. J., & Braunwald, E. (2017) · Circulation Research · doi:10.1161/circresaha.117.311059 · Cited by 1,403
Geisterfer-Lowrance, A. A. T., Kass, S., Tanigawa, G., Vosberg, H.-P., McKenna, W., Seidman, C. E., & Seidman, J. G. (1990) · Cell · doi:10.1016/0092-8674(90)90274-i · Cited by 1,380
Olivotto, I., Oreziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., Garcia-Pavia, P., Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31792-x · Cited by 1,296
Dilated Cardiomyopathy: Genetic Determinants and Mechanisms
McNally, E. M., & Mestroni, L. (2017) · Circulation Research · doi:10.1161/circresaha.116.309396 · Cited by 786
Mutations in Sarcomere Protein Genes as a Cause of Dilated Cardiomyopathy
Kamisago, M., Sharma, S. D., DePalma, S. R., Solomon, S., Sharma, P., McDonough, B., Smoot, L., Mullen, M. P., Woolf, P. K., Wigle, E. D., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432304 · Cited by 720
Teerlink, J. R., Clarke, C. P., Saikali, K. G., Lee, J. H., Chen, M. M., Escandon, R. D., Elliott, L., Bee, R., Habibzadeh, M. R., Goldman, J. H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61219-1 · Cited by 262
Cardiovascular Drug Development
Fordyce, C. B., Roe, M. T., Ahmad, T., Libby, P., Borer, J. S., Hiatt, W. R., Bristow, M. R., Packer, M., Wasserman, S. M., Braunstein, N., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.016 · Cited by 202
Myosin filament-based regulation of the dynamics of contraction in heart muscle
Brunello, E., Fusi, L., Ghisleni, A., Park-Holohan, S.-J., Ovejero, J. G., Narayanan, T., & Irving, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920632117 · Cited by 129
Indigenous impacts on North American Great Plains fire regimes of the past millennium
Roos, C. I., Zedeño, M. N., Hollenback, K. L., & Erlick, M. M. H. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805259115 · Cited by 115
Cited by
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Maron, M. S., Masri, A., Nassif, M. E., Barriales-Villa, R., Arad, M., Cardim, N., Choudhury, L., Claggett, B., Coats, C. J., Düngen, H.-D., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401424 · Cited by 348
Zhang, N., Zhang, Y., Xu, J., Wang, P., Wu, B., Lu, S., Lu, X., You, S., Huang, X., Li, M., et al. (2023) · Cell Research · doi:10.1038/s41422-023-00844-w · Cited by 292
Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy
Ostrominski, J. W., Guo, R., Elliott, P. M., & Ho, C. Y. (2023) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.04.018 · Cited by 42
Day, N. J., Kelly, S. S., Lui, L., Mansfield, T. A., Gaffrey, M. J., Trejo, J. B., Sagendorf, T. J., Attah, I. K., Moore, R. J., Douglas, C. M., et al. (2024) · Aging Cell · doi:10.1111/acel.14094 · Cited by 31
Metadata
- Authors
- Lehman, S. J., Crocini, C., & Leinwand, L. A.
- Venue
- Nature Reviews Cardiology
- Published
- 2022-03-18
- Volume
- 19
- Issue
- 6
- Pages
- 353-363
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- OpenAlex
- W4220889006
- Cited by
- 128
- References
- 11
- FWCI
- 8.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the sarcomere in inherited cardiomyopathies. https://app.cochat.ai/papers/10.1038/s41569-022-00682-0
- The paper
- Lehman, S. J., Crocini, C., & Leinwand, L. A. (2022). Targeting the sarcomere in inherited cardiomyopathies. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-022-00682-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.